ProCE Banner Activity

How I Approach CNS Metastases in Patients With HER2-Positive Metastatic Breast Cancer

Clinical Thought
Up to one half of patients with HER2+ MBC will develop brain metastases in the course of their disease. Read my thoughts on how I approach management of this challenging disease manifestation, including integration of recently approved HER2-targeted agents.

Released: April 29, 2020

Expiration: April 28, 2021

No longer available for credit.

Share

Faculty

Neelima Denduluri

Neelima Denduluri, MD, FASCO

Clinical Assistant Professor
Georgetown University
Washington, DC
Medical Oncologist
Virginia Cancer Specialists
Co-Director, Virginia Cancer Specialists Research Program
Associate Chair, US Oncology Breast Cancer Research Committee
Arlington, Virginia

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Puma Biotechnology, Inc.

Seagen

Faculty Disclosure

Primary Author

Neelima Denduluri, MD, FASCO

Clinical Assistant Professor
Georgetown University
Washington, DC
Medical Oncologist
Virginia Cancer Specialists
Co-Director, Virginia Cancer Specialists Research Program
Associate Chair, US Oncology Breast Cancer Research Committee
Arlington, Virginia

Neelima Denduluri, MD, has disclosed that she has received consulting fees from Seattle Genetics and funds for research support to her institution from Amgen, AstraZeneca, Daiichi Sankyo, Genentech, and Novartis.